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Advanced glycation end products (AGEs) have been implicated in the pathogenesis of sarcopenia. Our aim was to characterize
the relationship between serum carboxymethyl-lysine (CML), a major circulating AGE, and incident severe walking disability
(inability to walk or walking speed <0.4m/sec) over 30 months of followup in 394 moderately to severely disabled women,
≥65 years, living in the community in Baltimore, Maryland (the Women’s Health and Aging Study I). During followup, 154
(26.4%) women developed severe walking disability, and 23 women died. Women in the highest quartile of serum CML had
increased risk of developing of severe walking disability in a multivariate Cox proportional hazards model, adjusting for age and
other potential confounders. Women with elevated serum CML are at an increased risk of developing severe walking disability.
AGEs are a potentially modiﬁable risk factor. Further work is needed to establish a causal relationship between AGEs and walking
disability.
1.Introduction
Mobility diﬃculties are common among older adults and
are associated with poor quality of life [1], increased need
for care, and are predictive of death [2–4]. Understand-
ing the processes that lead to disability is important in
order to develop strategies to prevent or delay disability
in older adults. Lifestyle factors that may inﬂuence the
pathwaytodisabilityincludediet.Diethasbeenincompletely
characterized in relation to the development of disability.
Recent studies suggest that advanced glycation end products
(AGEs), which are active biomolecules formed by the non-
enzymaticcovalentbindingofsugarswithproteinsandother
molecules, may be related to muscle strength and physical
performance [5, 6]. The western diet is high in AGEs, which
are formed in high concentrations in foods that are prepared
at high temperatures. Thus, some foods are considered an
important exogenous source of AGEs. AGEs are thought
to be absorbed in the process of digestion, circulate in the
blood, and can be deposited in diﬀerent organs and tissues
[7].
Sarcopenia, or loss of muscle strength and muscle mass,
is an important factor underlying mobility diﬃculties such
as slow walking speed in older adults [8]. Older adults
have increased cross-linking of collagen and deposition of
AGEs in skeletal muscle [9]. In aging animals, cross-linking
of collagen is associated with increased muscle stiﬀness,
reducedmusclefunction[10,11],andaccumulationofAGEs2 Journal of Aging Research
[12]. AGEs may also play a role in sarcopenia through
upregulationofinﬂammationandendothelialdysfunctionin
the microcirculation of skeletal muscle through the receptor
for AGEs, or RAGE [13]. AGE-induced cross-linking of is
collagen elevated in older adults [14] and has been shown
to increase the stiﬀness of human articular cartilage [15].
The relationship between circulating AGEs and the
development of disability has not been characterized in
older adults. We hypothesized that women with elevated
serum carboxymethyl-lysine (CML), an advanced glycation
end product, had an increased risk of developing severe
walking disability. To address this hypothesis, we examined
the relationship between serum CML concentrations and
severe walking disability among older women living in the
community.
2.SubjectsandMethods
2.1. Study Population. Subjects in this study were women
who participated in the Women’s Health and Aging Study
I (WHAS I), a population-based study designed to evaluate
the causes and course of physical disability in older disabled
women living in the community. WHAS I participants were
recruited from an age-stratiﬁed random sample of women
aged 65 years and older selected from Medicare enrollees
residing in 12 contiguous-zip-code areas in Baltimore [16].
Women were screened to identify self-reported physical
disability that was categorized into four domains. The
domains of disability were ascertained in a 20- to 30-
minute home interview that included questions related to
(1) mobility and exercise tolerance, that is, walking for a
quarter of a mile, walking up 10 steps without resting,
getting in and out of bed or chairs; (2) upper extremity
function, that is, raising your arms up over your head,
using your ﬁngers to grasp or handle, lifting or carrying
something as heavy as ten pounds; (3) higher functioning
tasks (a subset of instrumental activities of daily living, not
including heavy housework, that is, using the telephone,
doing light housework, preparing your own meals, shopping
for personal items); (4) basic self-care tasks (a subset of
nonmobility dependent activities of daily living, i.e., bathing
or showering, dressing, eating, using the toilet). WHAS I
enrolled the one-third most disabled women ages 65 and
older, those with disability in two or more domains. Of
the 1409 women who met study eligibility criteria, 1002
agreed to participate in the study in 1992. There were no
major diﬀerences in sociodemographic or reported health
characteristics between eligible participants and those who
declined to participate [16].
At the 12-month follow-up visit (as baseline for the
present study), 879 women returned for followup, of which
580receivedablooddraw.CMLwasmeasuredin531women
who had walking speed measurements available. 119 had
severe walking disability, 412 did not have severe walking
disability, and of whom 394 who had at least one follow-up
visitthereafterwereincludedinthepresentstudy.Laboratory
measurements of serum CML were done at the 12-month
follow-up visit rather than at enrollment because of a greater
availability of serum aliquots from this visit.
2.2. Data Collection. Standardized questionnaires were
administered in the participant’s home by trained interview-
ers. Race was assessed in a questionnaire as black, white, or
other, current smoking as yes or no, and education as 0–8, 9–
11, 12, or more than 12 years as the highest level of formal
education achieved. Two weeks later, a trained registered
full-time study nurse practitioner examined each study
participant in her home, using a standardized evaluation
of physical performance and physical exam. Approximately
75% of women also consented to phlebotomy performed
during a separate visit by a trained phlebotomist who
followed a standardized protocol. The deﬁnitions for the
chronic diseases reported in this study were adjudicated
by WHAS coinvestigators based on standardized algorithms
that combined information from the questionnaire, physical
examination, and physician contact [16]. The Mini-Mental
State Examination (MMSE) was administered at enrollment.
Further details on the methods and sampling design of the
WHAS studies are published elsewhere [16].
The participant was asked to walk over a 4-meter course
foreachfollow-upvisit. Participants wereinstructedtostand
with both feet at the starting line and to start walking
after a speciﬁc verbal command. Timing began when the
command was given. In this test, the subject could use a
cane, a walker, or other walking aid, but not the aid of
another person. The times to complete the ﬁrst meter and
the entire path were recorded. The test was repeated three
times, twice at the woman’s usual pace, and once at her
fastest possible pace. The speed of the faster of the two usual-
pace walks was used in the analyses. The length of the walk
expressed in meters divided by the time in seconds was used
to calculate the average walking speed [16]. Women were
categorized as having severe walking disability based upon
being unable to walk or having a walking speed < 0.4m/sec
[17]. The 0.4m/sec cut-oﬀ point was approximately at the
top of the lowest quartile in the WHAS population at
baseline [18] and has been shown to predict functional
dependence [19]. Demographic characteristics, self-rated
health, and information about appetite and eating were
measured in the WHAS questionnaires. Chronic diseases
were adjudicated by WHAS coinvestigators based on the
questionnaire, physical examination, and physician contact
[16]. Vital status was determined through matching with the
National Death Index from the 12-month follow-up visit,
1993–96 through the end of 2000. The study protocol was
adherent to the Declaration of Helsinki. The Johns Hopkins
University Institutional Review Board approved the study
protocol, and written informed consent was obtained from
all participants.
2.3. Laboratory Studies. Nonfasting blood samples were
obtained by venipuncture between 9AM and 2PM. Blood
samples were delivered to Quest Diagnostics Laboratories
(formerly Ciba-Corning Laboratories, Baltimore, MD) on
the day of blood drawing for complete blood count and
creatinine measurements. Serum creatinine was measured
using the Jaﬀe method. Processing, aliquoting, and freezing
werecarriedoutattheCoreGeneticsLaboratoryoftheJohnsJournal of Aging Research 3
HopkinsUniversitySchoolofMedicinefollowingastandard-
ized protocol. Blood samples were stored continuously at
−70◦C until the time of analyses of serum carboxymethyl-
lysine (CML). CML is well characterized, circulating AGE,
and one of the dominant AGEs in tissue proteins [20]. CML
was measured using a competitive ELISA (AGE-CML ELISA,
Microcoat, Penzberg, Germany) [21]. This assay has been
validated [22], is speciﬁc, and shows no cross-reactivity with
other compounds [21]. Measurements were performed in
duplicate according to the protocol of the manufacturers,
andtheresultswereaveraged.Thewithin-assayandbetween-
assay coeﬃcients of variation for serum CML were 3% and
4%, respectively.
2.4. Statistical Analysis. Continuous variables were com-
pared using Wilcoxon rank-sum test. Categorical variables
were compared using chi-square tests. Body mass index
(BMI) was categorized as underweight (<18.5kg/m2), nor-
mal range (18.5–24.9kg/m2), overweight (≥25–29.9kg/m2)
and obese (≥30kg/m2)[ 23]. An MMSE score of <24 was
deﬁned as cognitive impairment [24]. Renal insuﬃciency
was deﬁned as estimated glomerular ﬁltration rate of
<60mL/min/1.73m2 using the Modiﬁcation of Diet in Renal
Disease equation of Levey and colleagues [25]. Plasma
CML was divided into quartiles, and the cut-oﬀ between
quartiles was 452.6, 558.8, and 689.1ng/mL. Grouped-
time Cox proportional hazards models [26] were used to
examinetheassociationsbetweenserumAGEsandtheriskof
developing severe walking disability because severe walking
disability was determined at six-month intervals. The length
of followup in longitudinal analyses was 30 months. Women
who died, or refused further participation, or were lost to
followup after a follow-up visit were censored according to
their severe walking disability status at their last visit in the
study.
During the 30 months following the original 12-month
follow-up visit (as the baseline for the present study), there
were 23 patients who died, 9 of them died after developing
severe walking disability whereas 14 of them died with
no severe walking disability until the last follow-up visit.
Cox proportional hazards models were used to examine the
associations between CML and risk of developing severe
walkingdisability.Asahighlysigniﬁcantassociationbetween
slow walking speed and death has been previously described
[27], it is a reasonable assumption that some women
developed severe walking disability prior to death. For those
who died without developing severe walking disability, ﬁrst,
the multiple imputation technique was used to impute the
data and then the complete data was analyzed; second, the
severewalkingdisabilitystatusknowndataonlywasanalyzed
with weighting by inverse probability weighting (IPW) on
the data [28]; ﬁnally, two sensitivity analyses were applied
to validate those two methods dealing with the incomplete
data: (1) treating all missing data because of death as severe
walking disability-free; (2) treating the missing data as severe
walking disability developed [29]. The statistical program
u s e dw a sS A S9 . 1( S A SI n s t i t u t e ,C a r y ,N C ) .T h el e v e lo f
signiﬁcance used in this study was P<0.05.
3. Results
There were 394 women who did not have severe walking
disabilityatbaselinehadserumcarboxymethyl-lysine(CML)
measurements available, and had at least one followup
involved in the present study. One hundred ﬁfty-four
(26.4%) of the women developed severe walking disability
during followup with an overall rate of severe walking
disability of 14.8 per 100 person-years. The characteristics
of women who did and did not develop severe walking
disability during followup are shown in Table 1.W o m e n
whodevelopedseverewalkingdisabilitywereolderandmore
likely to be aﬀected by congestive heart failure, peripheral
artery disease, and diabetes. There were no signiﬁcant
diﬀerences between women who developed and those who
didnotdevelopwalkingdisabilitybyrace,education,current
smoking, MMSE score, body mass index, hypertension,
coronary artery disease, stroke, depression, osteoarthritis,
chronic obstructive pulmonary disease, and renal insuﬃ-
ciency. Compared with the group of lower three quartiles of
CML, the patients in the group of highest quartile of CML
were more likely to develop severe walking disability.
Univariate Cox proportional hazards models were used
to examine the relationship between demographic and
health characteristics and the development of severe walk-
ing disability (Table 2). Highest quartile of CML, older
age, congestive heart failure, peripheral artery disease,
and diabetes mellitus were associated with an increased
risk of developing severe walking disability. Multivariable
Cox proportional hazards model that adjusted for age,
congestive heart failure, peripheral artery disease, diabetes
mellitus, and renal insuﬃciency are shown in four scenarios
(Table 3).
4. Discussion
The present study shows that older community-dwelling
women with elevated serum CML are at increased risk
of developing severe walking disability. These ﬁndings are
consistent with a previous, cross-sectional study which
showed that elevated plasma CML was associated with
slow walking speed in older community-dwelling men and
women [6]. The present study extends these ﬁndings and
shows that elevated CML is an independent predictor of the
development of severe walking disability.
These observations are consistent with the hypothesis
thatAGEsplayaroleinsarcopenia[13].IncreasedAGEsmay
contribute to increased stiﬀness in muscle tissue and reduced
viscoelastic properties of muscle and thus impair muscle
function [9]. Collagen is the main structural component
of the interstitial space of skeletal muscle and provides
elasticity when muscles contract [30]. Aging muscle is
characterized by an increase in pyridinium cross-linking
of collagen, which is enzymatically derived, and the non-
enzymatic accumulation of cross-linking AGEs. In adults
without diabetes, the concentration of pentosidine, a major
AGE in tissues, was found in skeletal muscle at greater than
two times concentration in older compared with younger
adults [9].4 Journal of Aging Research
Table 1: Characteristics of women who developed and did not develop severe walking disability in the women’s health and aging study I
(N = 394).
Characteristic Incident severe walking
disability (n = 104)
No incident severe walking
disability (n = 290) P
Age category (years) (%)
≤69 17.3 26.2
70–74.9 22.1 27.6




Race (white) (%) 69.2 75.5 0.21
Education <12 years (%) 62.1 60.3 0.75
Current smoking (%) 15.4 10.0 0.14
Body mass index (kg/m2)( % )
<18.5 3.2 2.8
18.5–24.9 27.7 23.2 0.83
25.0–29.9 35.1 36.8
≥30 34.0 37.2
MMSE score <24 (%) 15.4 9.7 0.11
Hypertension (%) 57.7 56.2 0.79
Coronary heart disease (%) 24.0 22.1 0.68
Congestive heart failure (%) 14.4 7.2 0.029
Peripheral artery disease (%) 26.0 15.5 0.018
Stroke (%) 1.0 2.8 0.29
Diabetes mellitus (%) 23.1 11.7 0.005
Depression (%) 15.4 11.4 0.29
Chronic obstructive pulmonary disease (%) 29.8 25.9 0.44
Renal insuﬃciency (%) 58.4 52.5 0.30
Osteoarthritis (%) 57.7 53.5 0.46
CML highest quartile (%) 33.7 22.4 0.02
Tendons transfer the forces generated by muscles to bone
and have elastic properties that aﬀect the muscle tendon
complex. AGEs are deposited in tendons and can aﬀect their
structural properties. In a rabbit model, cross-linking of
collagen by nonenzymatic glycation increased the structural
stiﬀness of Achilles tendon [31]. In humans, there was
as e v e n f o l dd i ﬀerence in concentrations of pentosidine in
the patellar tendon in older compared with younger men
[14]. Elevated AGEs are also associated with increased bone
rigidity [32] which is thought to occur through cross-linking
of collagen [33].
AGEs may also aﬀect skeletal muscle and tendons
through upregulation of inﬂammation via binding with
RAGE [34]. The carboxymethyl-lysine (CML) adduct of
AGEs has been identiﬁed as a signal-transducing ligand for
RAGE, both in vitro and in vivo [35]. Ligand binding with
RAGE triggers the induction of increased reactive oxygen
species, activation of NADPH oxidase, and upregulation of
inﬂammation through NF-κB and other signaling pathways
[36, 37]. Inﬂammatory mediators that are upregulated
through AGE and the NF-κB pathway include TNF-α,I L - 6 ,
and C-reactive protein [38].
A limitation of this study is that the results cannot
necessarily be extrapolated to men or to less disabled women
inthecommunity.TherearemanydiﬀerentAGEs,andinthe
present study, CML was the only AGE that was measured in
serum. However, other studies have shown that circulating
CML has a moderate correlation with other AGEs in the
blood such as pentosidine and methylglyoxal derivatives
[39]. Serum CML concentrations show a moderate corre-
lation with dietary intake of AGEs in older adults [39].
Serum CML concentrations have been reported to vary with
dietary intake of AGEs [40], but these ﬁndings have not been
corroborated by others [41, 42].
5. Conclusions
Older women with elevated plasma CML, an advanced
glycation end product, had greater risk of developing severe
walking disability. Whether modiﬁcation of dietary intake ofJournal of Aging Research 5
Table 2: Univariate Cox proportional hazard models for demographic and health characteristics and incidence of severe walking disability
in the women’s health and aging study I (N = 394).
Characteristic Univariate H.R. 95% C.I. P
Age (years)
≤69 1.00 — —
70–74.9 1.18 0.64, 2.18 0.60
75–79.9 0.93 0.46, 1.86 0.83
80–84.9 1.96 0.99, 3.89 0.05
85–89.9 2.35 1.28, 4.34 0.006
≥90 5.04 2.25, 11.26 <0.0001
Race (white) 0.76 0.50, 1.16 0.19
Education <12 years 1.12 0.75, 1.67 0.58
Current smoking 1.59 0.93, 2.70 0.09
Body mass index (kg/m2)1
<18.5 0.98 0.30, 3.25 0.98
18.5–24.9 1.00 — —
25.0–29.9 0.75 0.45, 1.26 0.28
≥30 0.75 0.45, 1.27 0.28
MMSE <24 1.59 0.93, 2.70 0.09
Hypertension 1.04 0.71, 1.54 0.84
Coronary heart disease 1.09 0.70, 1.71 0.70
Congestive heart failure 1.87 1.08, 3.24 0.03
Peripheral artery disease 1.74 1.12, 2.72 0.01
Stroke 0.46 0.06, 3.31 0.44
Chronic obstructive pulmonary disease 1.21 0.80, 1.85 0.37
Diabetes mellitus 1.79 1.13, 2.85 0.01
Depression 1.21 0.70, 2.09 0.49
Renal insuﬃciency 1.18 0.79, 1.75 0.42
Osteoarthritis 1.22 0.83, 1.81 0.32
CML highest quartile 1.68 1.11, 2.52 0.01
1For body mass index, 18.5–24.9kg/m2 w a su s e da st h er e f e r e n c ec a t e g o r y .
Table 3: Multivariate cox proportional hazard models for serum CML and development of severe walking disability, (N = 394)1.
Scenario H.R.2 95% C.I. P
(1) All women with missing data had multiple simulations to impute severe walking disability status prior
to death. 1.63 1.06, 2.49 0.03
(2) Inverse probability weighting method (IPW) 1.56 1.04, 2.36 0.03
(3) All women with missing data treated as censored, that is, no severe walking disability prior to death. 1.46 0.95, 2.23 0.08
(4) All women with missing data treated as developing severe walking disability prior to death. 1.54 1.04, 2.29 0.03
1All models adjusted for age, congestive heart failure, peripheral artery disease, diabetes mellitus, and renal insuﬃciency.
2Highest quartile of serum CML versus lower three quartiles.
AGEs can inﬂuence the pathway to disability in older adults
is not known.
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